Consistent with these preclinical data, IFN-β administration ameliorated arthritis in collagen-induced models [293,345]; however, in a multicenter, randomized, double-blind phase II trial, subcutaneous recombinant IFN-β failed to demonstrate efficacy in active RA [294]. Here, IFNB1 is linked to arthritic joint disease.